NOVATO, Calif. , Nov. 26, 2025 /PRNewswire/ -- Lighthouse Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company pioneering precision medicine to address major unmet medical needs, announced a poster presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 conference in San Diego, California on Wednesday, December 3, 2025, from 7:15 a.m. - 5:30 p.m. (P230).

The poster, titled " The SPRING Trial: Treatment of P. gingivalis–Positive Mild to Moderate Alzheimer's Disease with the Second-Generation Gingipain Inhibitor LHP588 ," highlights the rationale, design, and previous clinical data supporting the ongoing Phase 2 SPRING trial (NCT06847321). The National Institute on Aging (NIA) recently awarded $49.2 million to Lighthouse to conduct the SPRING trial, undersc

See Full Page